Researchers at Brigham and Women’s Hospital have developed a pathogen capture and neutralizing nasal spray (PCANS) that can protect against viral and bacterial respiratory infections. The spray forms a gel-like matrix that traps, immobilizes, and neutralizes germs within the nasal cavity. Preclinical studies show that PCANS is effective against a broad spectrum of pathogens, including the flu virus and SARS-CoV-2. While human studies are needed, the results are promising, with PCANS demonstrating exceptional efficacy in blocking infections in mice. The researchers are also investigating PCANS’ potential to block allergens. This innovative approach could offer a new way to reduce the transmission of respiratory diseases.
https://medicalxpress.com/news/2024-09-preclinical-drug-free-nasal-spray.html